Ovarian cancer risk factors by tumor dominance, a surrogate for cell of origin

International Journal of Cancer

Volumn 133, Issue 3, 2013, Pages 730-739

  Kotsopoulos, Joanne ^a,b   Terry, Kathryn L ^c,d   Poole, Elizabeth M ^c,d   Rosner, Bernard ^c,d   Murphy, Megan A ^c,d   Hecht, Jonathan L ^e   Crum, Christopher P ^c   Missmer, Stacey A ^c,d   Cramer, Daniel W ^c,d   Tworoger, Shelley S ^c,d  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cell of origin; epidemiology; ovarian cancer; risk factors

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CASE CONTROL STUDY; CLEAR CELL CARCINOMA; COHORT ANALYSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; UTERINE TUBE; UTERINE TUBE LIGATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; AGE FACTORS; CARCINOMA, ACINAR CELL; CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; COHORT STUDIES; ENDOMETRIOSIS; FALLOPIAN TUBE NEOPLASMS; FALLOPIAN TUBES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; REPRODUCTIVE HISTORY; RISK FACTORS;

EID: 84878018442     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28064     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts and Figures, 2011. Atlanta, Georgia, USA: American Cancer Society, 2011.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Auersperg N, Wong AS, Choi KC, et al. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-88.
4. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211: 26-35.
5. Levanon K, Ng V, Piao HY, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010; 29: 1103-13.
6. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195: 451-6.
7. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol 2007; 31: 161-9.
8. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol 2005; 106: 1327-34.
9. Jarboe EA, Folkins AK, Drapkin R, et al. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology 2008; 53: 127-38.
10. Kurman RJ, Shih Ie M,. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34: 433-43.
11. Beral V, Doll R, Hermon C, et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-14.
12. Rice MS, Murphy MA, Tworoger SS,. Tubal ligation, hysterectomy and ovarian cancer: a meta-analysis. J Ovarian Res 2012; 5: 13.
13. Chiaffarino F, Parazzini F, Bosetti C, et al. Risk factors for ovarian cancer histotypes. Eur J Cancer 2007; 43: 1208-13.
14. Gates MA, Rosner BA, Hecht JL, et al. Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45-53.
15. Kurian AW, Balise RR, McGuire V, et al. Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 2005; 96: 520-30.
16. Modugno F, Ness RB, Wheeler JE,. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001; 11: 568-74.
17. Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144: 363-72.
18. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003; 158: 629-38.
19. Yang HP, Trabert B, Murphy MA, et al. Ovarian cancer risk factors by histologic subtypes in the NIH-AARP diet and health study. Int J Cancer 2012; 131: 938-48.
20. Roh MH, Kindelberger D, Crum CP,. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 2009; 33: 376-83.
21. Rich-Edwards JW, Corsano KA, Stampfer MJ,. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol 1994; 140: 1016-19.
22. Tworoger SS, Hecht JL, Giovannucci E, et al. Intake of folate and related nutrients in relation to risk of epithelial ovarian cancer. Am J Epidemiol 2006; 163: 1101-11.
23. Marshall RJ, Chisholm EM,. Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer. Stat Med 1985; 4: 337-44.
24. Lunn M, McNeil D,. Applying Cox regression to competing risks. Biometrics 1995; 51: 524-32.
25. Soegaard M, Jensen A, Hogdall E, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1160-6.
26. Modugno F, Ness RB, Cottreau CM,. Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology 2002; 13: 467-71.
27. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30: 230-6.
28. Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011; 11: 719-25.
29. Brugghe J, Baak JPA, Wiltshaw E, et al. Further evaluation of reproducibility and prognostic value of histologic typing and grading in FIGO stage I ovarian cancer patients without systemic locoregional adjuvant treatment. Int J Gynecol Cancer 1995; 5: 262-68.
30. Whittemore AS, Harris R, Itnyre J, et al. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136: 1175-83.
31. Risch HA,. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998; 90: 1774-86.
32. Cramer DW, Titus-Ernstoff L, McKolanis JR, et al. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1125-31.
33. Fathalla MF,. Incessant ovulation-a factor in ovarian neoplasia? Lancet 1971; 2: 163.
34. Semere LG, Ko E, Johnson NR, et al. Endometrial intraepithelial neoplasia: clinical correlates and outcomes. Obstet Gynecol 2011; 118: 21-8.
35. Kappou D, Matalliotakis M, Matalliotakis I,. Medical treatments for endometriosis. Minerva Ginecol 2010; 62: 415-32.
36. Park H, Seok JM, Yoon BS, et al. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet 2012; 285: 473-8.
37. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012; 13: 385-94.
38. Cibula D, Widschwendter M, Zikan M, et al. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand 2011; 90: 559-63.
39. Beining RM, Dennis LK, Smith EM, et al. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol 2008; 18: 492-9.
40. Ortiz ME, Croxatto HB,. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007; 75: S16-S30.
41. Larsson B, Ljung B, Hamberger L,. The influence of copper on the in vitro motility of the human fallopian tube. Am J Obstet Gynecol 1976; 125: 682-90.
42. Lundin E, Dossus L, Clendenen T, et al. C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy). Cancer Causes Control 2009; 20: 1151-9.
43. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 2007; 109: 933-41.
44. Toriola AT, Grankvist K, Agborsangaya CB, et al. Changes in pre-diagnostic serum C-reactive protein concentrations and ovarian cancer risk: a longitudinal study. Ann Oncol 2011; 22: 1916-21.
45. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 799-810.
46. Ali-Fehmi R, Semaan A, Sethi S, et al. Molecular typing of epithelial ovarian carcinomas using inflammatory markers. Cancer 2011; 117: 301-9.
47. Pinheiro SP, Tworoger SS, Cramer DW, et al. Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts. Am J Epidemiol 2009; 169: 1378-87.
48. Prizment AE, Folsom AR, Anderson KE,. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 2010; 19: 435-42.
49. Lacey JV, Jr, Sherman ME, Hartge P, et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer 2004; 108: 281-6.
50. Fairfield KM, Hunter DJ, Fuchs CS, et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002; 13: 535-42.